Roche has secured FDA clearance for Elecsys pTau217, a single-biomarker blood test capable of supporting both rule-in and rule-out assessment of Alzheimer’s-associated amyloid pathology across primary and specialty care.
Foundayo became the first approved nonpeptide small-molecule GLP-1 obesity drug in 2026, replacing injectable peptide chemistry with a tablet that can be taken without food or water restrictions.
FDA approves Lantheus’ Tauklarify for Alzheimer’s tau PET imaging. See what the scan detects, where errors arise and what could limit access.
Eli Lilly and Company has created a limited expanded-access pathway for adults with severe, treatment-resistant obesity, even as regulators warn that products sold online as retatrutide are unapproved, potentially contaminated and illegal to compound.
Neurocrine Biosciences has initiated a first-in-human Phase 1 study of NBIP-1968, a once-weekly experimental obesity treatment designed to activate the GLP-1, GIP and glucagon receptors through a single molecule. The August 7, 2026 development marks Neurocrine Biosciences’ entry into clinical testing with an incretin-based obesity candidate. The study will initially examine single ascending doses in
RiboX Therapeutics has received clearance from the United States Food and Drug Administration to begin clinical testing of RXIM002, an experimental treatment designed to create temporary anti-CD19 CAR-T cells directly inside the body of a patient with autoimmune disease. The August 8, 2026 investigational new drug clearance allows RiboX Therapeutics to initiate the Phase 1
Eli Lilly and Company has secured an expedited United States regulatory pathway for olomorasib in a rare, previously treated pancreatic cancer population. The designation increases FDA engagement around the programme, but the investigational therapy still needs a pancreatic cancer-specific evidence package capable of supporting approval.
Verdiva Bio has begun Phase 1 testing of weekly oral amylin candidate VRB-103. See what the trial can prove and what remains uncertain.
Eli Lilly and Resilience are investing $750 million to expand U.S. KwikPen production in Ohio. See why manufacturing execution now matters.
Ascletis says ASC37 beat tirzepatide in obese mice, but human dosing, safety and durability remain untested ahead of a planned U.S. IND.